Lifemin

Lisdexamfetamine dimesylate, the active ingredient in Lifemin, is a amphetamine (central nervous system stimulant) presented as an oral formulation for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder and binge eating disorder in appropriate patient populations.

GNH USA supplies Lifemin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lifemin is a central nervous system stimulant used to manage conditions within the neurobehavioral disorder family.

Attention deficit hyperactivity disorder: improves focus, reduces hyperactivity and impulsivity in children and adults. Binge eating disorder: decreases the frequency of binge‑eating episodes and helps control appetite. Impulse control disorders: may aid in reducing impulsive behaviors associated with certain psychiatric conditions.

Lifemin may cause a range of adverse reactions, from mild to severe. Patients should be aware of both common and rare events.

Common Side Effects: - Insomnia - Decreased appetite - Dry mouth - Headache - Weight loss - Irritability

Serious or Rare Side Effects: - Cardiovascular events such as tachycardia or hypertension - Psychosis or severe mood changes - Seizures - Suicidal thoughts or behaviors - Severe allergic reactions including rash or angioedema - Pulmonary hypertension

Before initiating Lifemin, clinicians should evaluate several safety considerations.

Cardiovascular assessment: obtain baseline blood pressure and heart rate. Psychiatric history: review for prior psychosis, bipolar disorder, or severe anxiety. Potential for abuse: assess risk of dependence or misuse. Growth monitoring: regularly track height and weight in pediatric patients. Concomitant MAO inhibitors: avoid use within 14 days of MAOI therapy. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Lifemin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Other CNS stimulants: additive sympathomimetic effects. - Serotonergic agents: potential serotonin syndrome.

Moderate Interactions (Monitor Closely):\n- Antihypertensive agents: may reduce blood‑pressure‑lowering effect. - SSRIs or SNRIs: may increase stimulant‑related side effects. - Antacids: may alter gastrointestinal absorption of the prodrug.